A threat to decentralised care for drug-resistant tuberculosis

No abstract is available for this paper.

• Publication year

  2020

• Venue

  The Lancet Respiratory Medicine

• Publication date

  2020-09-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S2213-2600(20)30392-1PMID 33007284PMCID 7524514
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Factors influencing diagnosis and treatment initiation for multidrug-resistant/rifampicin-resistant tuberculosis in six sub-Saharan African countries: a mixed-methods systematic review

  2020cited by this paper
• Provider perspectives of the introduction and implementation of care for drug-resistant tuberculosis patients in district-level facilities in South Africa: a qualitative study

  2020cited by this paper
• The potential impact of COVID-19-related disruption on tuberculosis burden

  2020cited by this paper
• GADSA: Decision Support App for Antibiotics Prescribing in Nigeria

  2019cited by this paper
• Incidence and predictors of lost to follow-up among drug-resistant tuberculosis patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: a retrospective follow-up study

  2019cited by this paper
• mHealth for Clinical Decision-Making in Sub-Saharan Africa: A Scoping Review

  2017cited by this paper
• Decentralized care for multidrug-resistant tuberculosis: a systematic review and meta-analysis

  2017cited by this paper
• Grand Challenges in Digital Health

  2015cited by this paper

• Longitudinal phenotypic and genomic evidence revealing increased risk of drug resistance accumulation in tuberculosis patients in the counties of central China

  2025cites this paper
• Self-driven solutions and resilience adapted by people with drug-resistant tuberculosis and their caregivers in Bengaluru and Hyderabad, India: a qualitative study

  2024cites this paper
• Drug-Resistant Tuberculosis and COVID-19: A Scoping Review on a New Threat to Antimicrobial Resistance

  2023cites this paper
• Tuberculose droga-resistente e COVID-19: revisão de escopo de uma nova ameaça à resistência microbiana a medicamentos

  2023cites this paper
• Patient-centered approach to the management of drug-resistant tuberculosis in France: How far off the mark are we?

  2022cites this paper
• Re-evaluating the merits of decentralization as a core strategy for effective delivery of drug-resistant tuberculosis care in Pakistan

  2022cites this paper
• Following Guidelines for Drug-Resistant Tuberculosis: “Yes, it’s a challenge”

  2021cites this paper